Evidence map›Paper›PMID 31519196›Full record

ArticleBMC cardiovascular disorders2019

Peripheral arterial disease and systematic detection of circulating tumor cells: rationale and design of the DETECTOR prospective cohort study.

Alexandra Yannoutsos, Manon Fontaine, Alexandre Galloula, Diane Damotte, Gilles Chatellier, Patrizia Paterlini-Bréchot, Guy Meyer, Jean Pastre, Véronique Duchatelle, Valéria Marini and 15 more

Registry-linked trialOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in BMC cardiovascular disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02849041 (Screening of Tobacco-induced Cancers by Low-dose CT-scanner and Identification of Circulating Tumor Cells), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02849041 naunknown statusnot on this map

Screening of Tobacco-induced Cancers by Low-dose CT-scanner and Identification of Circulating Tumor Cells

TypeinterventionalSponsorFondation Hôpital Saint-JosephRan2017 to 2023Enrolled176ConditionsTobacco, Cancer, Screening, PsychologyArmsmedical imaging, Identification of Circulating Tumor Cells, Psychological Questionnaires
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 1 country.

Alexandra YannoutsosGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Manon FontaineUniversité Paris XIII, Villetaneuse, France.
Alexandre GalloulaHôpital Européen Georges Pompidou, Assistance Publique - Hôpitaux de Paris, 75014, Paris, France.
Diane DamotteUniversité Paris Descartes, Sorbonne Paris Cité, Paris, France.
Gilles ChatellierUniversité Paris Descartes, Sorbonne Paris Cité, Paris, France.
Patrizia Paterlini-BréchotUniversité Paris Descartes, Sorbonne Paris Cité, Paris, France.
Guy MeyerUniversité Paris Descartes, Sorbonne Paris Cité, Paris, France.
Jean PastreUniversité Paris Descartes, Sorbonne Paris Cité, Paris, France.
Véronique DuchatelleGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Valéria MariniGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Karl-Léo SchweringUniversité Paris XIII, Villetaneuse, France.
Isabelle LazarethGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Parinaz GhaffariGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Audrey StansalGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Hélène SansonGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Cécile LabrousseGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Hélène BeaussierGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Nesrine Ben NasrGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Marc ZinsGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Sergio SalmeronGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Emmanuel MessasUniversité Paris Descartes, Sorbonne Paris Cité, Paris, France.
Jean-Patrick LajonchèreGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Joseph EmmerichGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Pascal PriolletGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France.
Jean TrédanielGroupe Hospitalier Paris Saint Joseph, 185 rue Raymond Losserand, 75 014, Paris, France. jtredaniel@hpsj.fr.ORCID 0000-0003-1369-5668
Hôpital Paris Saint-Joseph · FRDélégation Paris 5 · FRUniversité Sorbonne Paris Nord · FRAssistance Publique – Hôpitaux de Paris · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSmoking is a strong risk factor for cancer and atherosclerosis. Cancer mortality, especially from lung cancer, overtakes cardiovascular (CV) death rate in patients with peripheral arterial disease (PAD). Only a few patients with lung cancer after PAD management may benefit from surgical excision. Circulating tumor cells (CTC) associated with low-dose chest CT (LDCT) may improve early cancer detection. This study focuses on a screening strategy that can address not only lung cancer but all tobacco-related cancers in this high-risk population.

methodsDETECTOR Project is a prospective cohort study in two French University hospitals. Participants are smokers or former smokers (≥30 pack-years, quitted ≤15 years), aged ≥55 to 80 years, with atherosclerotic PAD or abdominal aortic aneurysm. After the first screening round combining LDCT and CTC search on a blood sample, two other screening rounds will be performed at one-year interval. Incidental lung nodule volume, volume doubling time and presence of CTC will be taken into consideration for adapted diagnostic management. In case of negative LDCT and presence of CTC, a contrast enhanced whole-body PET/CT will be performed for extra-pulmonary malignancy screening. Psychological impact of this screening strategy will be evaluated in population study using a qualitative methodology. Assuming 10% prevalence of smoking-associated cancer in the studied population, a total of at least 300 participants will be enrolled. DISCUSSION: Epidemiological data underline an increase incidence in cancer and related death in the follow-up of patients with PAD, compared with the general population, particularly for tobacco-related cancers. The clinical benefit of a special workup for neoplasms in patients with PAD and a history of cigarette smoking has never been investigated. By considering CTCs detection in this very high-risk selected PAD population for tobacco-induced cancer, we expect to detect earlier pulmonary and extra-pulmonary malignancies, at a potentially curable stage.

trial registrationThe study was registered in the French National Agency for Medicines and Health Products Safety (No N° EUDRACT_ID RCB: 2016-A00657-44) and was approved by the ethics Committee for Persons Protection (IRB number 1072 and n° initial agreement 2016-08-02; ClinicalTrials.gov identifier NCT02849041).

Indexed as

Early Detection of CancerAgedAged, 80 and overEx-SmokersFemaleFranceHumansIncidenceMaleMiddle AgedMultidetector Computed TomographyNeoplasmsNeoplastic Cells, CirculatingPeripheral Arterial DiseasePositron Emission Tomography Computed TomographyPredictive Value of TestsCancerCirculating tumor cellsScreeningTobacco

Identifiers

PMID31519196
PMCPMC6743149
OpenAlexW2972413723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.